Comparative Pharmacology
Head-to-head clinical analysis: AMPHETAMINE versus DEXEDRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHETAMINE versus DEXEDRINE.
AMPHETAMINE vs DEXEDRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amphetamine is a central nervous system stimulant that promotes release of monoamines (dopamine, norepinephrine, and serotonin) from presynaptic terminals and inhibits their reuptake, leading to increased synaptic concentrations. It also reversibly inhibits monoamine oxidase (MAO) and may directly stimulate postsynaptic receptors.
Dextroamphetamine is a central nervous system stimulant that enhances the activity of dopamine and norepinephrine in the brain by blocking their reuptake and increasing their release from presynaptic terminals.
5-60 mg/day orally, divided into 2-3 doses; immediate-release: initial 5 mg once or twice daily, increase by 5 mg increments weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly
5–60 mg/day orally in divided doses, typically 5–20 mg 1–3 times daily; use immediate-release or extended-release formulations per indication.
None Documented
None Documented
Clinical Note
moderateAmphetamine + Torasemide
"Amphetamine may increase the hypotensive activities of Torasemide."
Clinical Note
moderateAmphetamine + Tranilast
"Amphetamine may decrease the sedative activities of Tranilast."
Clinical Note
moderateHydroxyamphetamine + Tranilast
"Hydroxyamphetamine may decrease the sedative activities of Tranilast."
Clinical Note
moderateDextroamphetamine + Tranilast
"Dextroamphetamine may decrease the sedative activities of Tranilast."
Terminal elimination half-life: 10-13 hours (adults) for immediate-release formulations; prolonged to 12-14 hours in chronic use. Clinical context: Half-life correlates with duration of action; twice-daily dosing may be needed.
Terminal elimination half-life is 4-6 hours for dextroamphetamine; clinical effects last longer due to CNS accumulation
Primarily renal (70-80% as unchanged drug and metabolites); minor biliary/fecal (approximately 2-5%). Urinary pH-dependent: acidic pH enhances elimination, alkaline pH reduces it.
Renal: 30-45% unchanged, 50-60% as deaminated metabolites; fecal: minor (<5%)
Category D/X
Category C
CNS Stimulant
CNS Stimulant